162 related articles for article (PubMed ID: 20223922)
21. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
22. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.
Armstrong F; Lamant L; Hieblot C; Delsol G; Touriol C
Eur J Cancer; 2007 Mar; 43(4):640-6. PubMed ID: 17276053
[TBL] [Abstract][Full Text] [Related]
23. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.
Fawal M; Armstrong F; Ollier S; Dupont H; Touriol C; Monsarrat B; Delsol G; Payrastre B; Morello D
Blood; 2006 Oct; 108(8):2780-8. PubMed ID: 16835382
[TBL] [Abstract][Full Text] [Related]
24. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
26. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
Gascoyne RD; Lamant L; Martin-Subero JI; Lestou VS; Harris NL; Müller-Hermelink HK; Seymour JF; Campbell LJ; Horsman DE; Auvigne I; Espinos E; Siebert R; Delsol G
Blood; 2003 Oct; 102(7):2568-73. PubMed ID: 12763927
[TBL] [Abstract][Full Text] [Related]
27. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
[TBL] [Abstract][Full Text] [Related]
28. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
Piva R; Pellegrino E; Mattioli M; Agnelli L; Lombardi L; Boccalatte F; Costa G; Ruggeri BA; Cheng M; Chiarle R; Palestro G; Neri A; Inghirami G
J Clin Invest; 2006 Dec; 116(12):3171-82. PubMed ID: 17111047
[TBL] [Abstract][Full Text] [Related]
29. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
30. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
31. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.
Ambrogio C; Voena C; Manazza AD; Piva R; Riera L; Barberis L; Costa C; Tarone G; Defilippi P; Hirsch E; Boeri Erba E; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Blood; 2005 Dec; 106(12):3907-16. PubMed ID: 16105984
[TBL] [Abstract][Full Text] [Related]
32. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Fernandez-Vidal A; Mazars A; Gautier EF; Prévost G; Payrastre B; Manenti S
Cell Cycle; 2009 May; 8(9):1373-9. PubMed ID: 19305144
[TBL] [Abstract][Full Text] [Related]
34. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
Lawrence B; Perez-Atayde A; Hibbard MK; Rubin BP; Dal Cin P; Pinkus JL; Pinkus GS; Xiao S; Yi ES; Fletcher CD; Fletcher JA
Am J Pathol; 2000 Aug; 157(2):377-84. PubMed ID: 10934142
[TBL] [Abstract][Full Text] [Related]
35. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines.
Dirks WG; Fähnrich S; Lis Y; Becker E; MacLeod RA; Drexler HG
Int J Cancer; 2002 Jul; 100(1):49-56. PubMed ID: 12115586
[TBL] [Abstract][Full Text] [Related]
36. The t(2;5) in human lymphomas.
Kadin ME; Morris SW
Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
[TBL] [Abstract][Full Text] [Related]
37. Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence.
Cheuk W; Chan JK
Pathology; 2001 Feb; 33(1):7-12. PubMed ID: 11280613
[TBL] [Abstract][Full Text] [Related]
38. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
[TBL] [Abstract][Full Text] [Related]
39. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
[TBL] [Abstract][Full Text] [Related]
40. Pathobiology of ALK+ anaplastic large-cell lymphoma.
Amin HM; Lai R
Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]